stockrowiRhythm Holdings, Inc.
IRTC Healthcare Medical Devices
iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
- Revenue
- +14.9%
- EPS
- −462.5%
- Free cash flow
- −157.6%
- Total debt
- +0.48%
Quarter to September 2026, against a year earlier
Follow IRTC
Alert me
iRhythm Holdings, Inc. (IRTC) Return on invested capital
iRhythm Holdings, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −11.4%, up 5.0 percentage points from fiscal 2025 (−16.4%). Over the past ten years it has ranged from −1,864.7% (fiscal 2015) to −16.4% (fiscal 2025) — the current reading is the highest in ten years. That is below the Medical Devices industry median of −5.27% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −16.4% | 19.35 |
| FY2024 | −35.8% | 34.52 |
| FY2023 | −70.3% | 45.15 |
| FY2022 | −115.4% | (14.27) |
| FY2021 | −101.2% | (31.89) |
| FY2020 | −69.3% | 45.59 |
| FY2019 | −114.9% | 213.63 |
| FY2018 | −328.5% | (174.09) |
| FY2017 | −154.4% | (102.19) |
| FY2016 | −52.2% | 1,812.52 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| TMDX TransMedics Group, Inc. compare | 48.0% |
| UFPT UFP Technologies, Inc. compare | 11.2% |
| LIVN LivaNova PLC compare | 9.14% |
| HAE Haemonetics Corporation compare | 6.31% |
| ITGR Integer Holdings Corporation compare | 3.16% |
| NEOG Neogen Corporation compare | −0.17% |
| AXGN AxoGen, Inc. compare | −5.27% |
| IRTC iRhythm Holdings, Inc. | −11.4% |
| TXG 10x Genomics compare | −20.2% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on IRTC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement